# A Randomized Study of Epigenetic Priming Using Decitabine With Front Line Induction Chemotherapy Compared With Immediate Induction Chemotherapy in Pediatric Acute Myelogenous Leukemia (AML) Subjects

> **NCT00943553** · PHASE2 · WITHDRAWN · sponsor: **Eisai Inc.**

## Conditions studied

- Acute Myelogenous Leukemia (AML)

## Interventions

- **DRUG:** decitabine Induction Chemotherapy
- **DRUG:** Induction Chemotherapy

## Key facts

- **NCT ID:** NCT00943553
- **Lead sponsor:** Eisai Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** WITHDRAWN
- **Start date:** 2010-06
- **Primary completion:** 2011-08
- **Final completion:** —
- **Target enrollment:** 0 (ACTUAL)
- **Why stopped:** Terminated by Sponsor
- **Last updated:** 2015-04-13


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00943553

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00943553, "A Randomized Study of Epigenetic Priming Using Decitabine With Front Line Induction Chemotherapy Compared With Immediate Induction Chemotherapy in Pediatric Acute Myelogenous Leukemia (AML) Subjects". Retrieved via AI Analytics 2026-06-26 from https://api.ai-analytics.org/clinical/NCT00943553. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*